The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant and the most recent key real-world data releases that have been published relative to the use of reversal or repletion strategies in the anticoagulated patient. This enduring activity was initially presented as a satellite symposium held during the AC Forum's 17th National Conference on Anticoagulation Therapy on April 2, 2023, in San Francisco, CA.